CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
about
Pharmacogenetics of antipsychotics.Realities and expectations of pharmacogenomics and personalized medicine: impact of translating genetic knowledge into clinical practice.Length of psychiatric hospitalization is correlated with CYP2D6 functional status in inpatients with major depressive disorder.Implementation of CYP2D6 genotyping in psychiatry.CYP2D6 variation, behaviour and psychopathology: implications for pharmacogenomics-guided clinical trialsAntipsychotic drug toxicology in children.Role of cytochrome P-450 genetic polymorphisms in oral carcinogenesis.CYP2D6 genetic polymorphism and psychiatry patients' hospitalization period.Guidance of pharmacotherapy in a complex psychiatric case by CYP450 DNA typing.Impact of depression mood disorder on the adverse drug reaction incidence rate of anticancer drugs in cancer patients.CYP2D6 genotyping in paediatric patients with autism treated with risperidone: a preliminary cohort study.BCHE and CYP2D6 genetic variation in Alzheimer's disease patients treated with cholinesterase inhibitors.Copy number variation and gene rearrangements in CYP2D6 genotyping using multiplex ligation-dependent probe amplification in Koreans.Research Highlights
P2860
Q33836837-84E3A02C-A095-44E6-9AA3-A0FB366765FBQ34131354-8BBBE0D8-0CA3-4306-A3D9-4884E5C2C955Q37016541-9823DB5D-F190-453B-9865-11B35D7BBAFFQ37538787-D3CD72CA-0C60-44CC-AE3C-6C55A9E76747Q37678050-879EBD17-B68F-4FF7-AD5C-07B1A854A9A4Q37852719-64E18BB4-2CAB-4341-9BD7-EF11AD3A8593Q37906754-39E01E78-2D37-4879-94AD-80B8D010901CQ45224861-6FBF1E71-E490-41B6-A81F-B0782AB9B7CEQ46563320-6AEEC4C3-60E7-47D9-A50D-066D56E2A37EQ48930749-B6DC9563-D914-4887-BB0D-71624BAAD3E4Q50306978-17BB5223-1E20-46B8-8A74-B029C1D22F94Q50800255-B14C4EB7-0737-4E60-9879-0B471283D2C1Q50938560-90B246B2-9EB4-4E1D-8D10-51D9FFC43315Q57585792-F27F5A55-5B94-4E98-8EE9-01DAD956872F
P2860
CYP2D6 genotyping for psychiatric patients treated with risperidone: considerations for cost-effectiveness studies.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@en
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@nl
type
label
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@en
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@nl
altLabel
CYP2D6genotyping for psychiatr ...... for cost–effectiveness studies
@en
prefLabel
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@en
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@nl
P2093
P2860
P356
P1433
P1476
CYP2D6 genotyping for psychiat ...... or cost-effectiveness studies.
@en
P2093
Adrián Llerena
David Gurwitz
Dolores Ibarreta
Emma Gutiérrez de Mesa
Julia Kirchheiner
P2860
P304
P356
10.2217/PGS.09.15
P577
2009-04-01T00:00:00Z